deltatrials
Completed PHASE2 NCT00120185

Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Naïve HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART

Sponsor: Chiron Corporation

Conditions HIV Infections
Interventions Interleukin-2
Updated 5 times since 2017 Last updated: Dec 21, 2011 Started: Dec 31, 2003 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

Listed as NCT00120185, this PHASE2 trial focuses on HIV Infections and remains completed. Sponsored by Chiron Corporation, it has been updated 5 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chiron Corporation
  • French National Agency for Research on AIDS and Viral Hepatitis
Data source: French National Agency for Research on AIDS and Viral Hepatitis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Paris, France